Danish weight-loss drug maker Novo reported third-quarter results ahead of expectations early Wednesday, as sales of its Wegovy pill far exceeded estimates after a turbulent year in which it fell behind rival Eli Lilly. Third-quarter sales reached 79.2 billion Danish kroner ($11.9 billion), up 4% year on year and above FactSet estimates of 73.6 billion kroner. Adjusted operating profit (EBIT) came in at 31.7 billion kroner, versus an expected 28.6 billion kroner. The company now expects adjusted revenue and operating profit growth of between negative 2% and 2% at constant exchange rates, up from its previous outlook of negative 6% to flat.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
earningspharmaceuticalsweight-loss drugsNovo Nordisk
Open a keyword to see other news on the same topic.
Related news
- Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Novo Nordisk presented a post hoc analysis of a Phase 3 CagriSema trial at The Menopause Society meeting: after 68 weeks, 2,309 women lost almost 25% of body weight on average, versus 3% on placebo. Among 1,902 women with menopause-related overweight or obesity, mean loss ranged from 23% to nearly 27%, while placebo averaged 2%. These results beat or match Wegovy (just under 15%) and Zepbound (nearly 21%), though in the head-to-head Redefine 4 trial, tirzepatide, Zepbound's molecule, showed similar or slightly higher efficacy, nearly 26% at the maximum dose. The author argues CagriSema is unlikely to win back market share from Eli Lilly, so investors should watch Novo's other pipeline programs, and notes the figures assume patients use the drug as directed.
- After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?
Eli Lilly reported third-quarter revenue up 39% to more than $24 billion, driven mainly by its weight loss portfolio. Mounjaro sales rose 65% to over $10 billion and Zepbound climbed 49% to $5.3 billion, while 40% of new patients starting an oral obesity medicine chose Foundayo. Lilly holds 63% of the U.S. market, and the stock is trading at a record high above $1,300, at 42x forward earnings estimates versus more than 70x in 2024. The article argues the weight loss market still has room to expand, since only 3% to 10% of potential U.S. patients access weight loss care, and that late-stage candidates such as retatrutide add to the growth outlook.
- Lilly’s Weight-Loss Machine Gets Even Bigger
Mounjaro and Zepbound once again drove a strong earnings beat for Lilly, along with a guidance upgrade worth billions of dollars. However, the company's new obesity pill is trailing Novo Nordisk from the start.
- Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Viking Therapeutics has started two phase 3 trials, SUNRISE-1 and SUNRISE-2, for the oral form of its weight loss drug VK2735, alongside its ongoing injectable phase 3 trials. Investors had been shaken by the phase 2 oral trial (VENTURE-Oral), where 20% of treated participants discontinued due to adverse events and the stock fell sharply, although efficacy over 13 weeks was good. The author argues the phase 3 design is different: 13% of the phase 2 placebo group also stopped due to adverse events, phase 2 used a more aggressive titration, and phase 3 runs 68 weeks. CEO Brian Lian said that in phase 2 patients took 4 tablets that were fairly large, and phase 3 aims for smaller tablets and fewer of them. Phase 3 doses are also lower, at 27.5 mg, 35 mg and 55 mg, compared with 15 mg to 120 mg in phase 2.
- Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Regeneron (REGN) has at least two promising weight-loss candidates in its pipeline. Olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones; in a Phase 3 study in China it led to mean weight loss of up to 19% over 48 weeks, with lower gastrointestinal adverse event rates than some competing drugs, though late-stage U.S. trials are still needed. Trevogrumab is not a weight-loss drug but is designed to be used alongside anti-obesity medicines to help preserve lean mass; in a Phase 2 study with Novo's semaglutide, lean mass preservation reached up to 42.5% versus 7.3% with semaglutide plus placebo. Dupixent, an eczema medicine co-marketed with Sanofi, remains the main growth driver: Regeneron's second-quarter revenue rose 17% year over year to $4.3 billion, and Dupixent's global sales increased 38% to $6 billion. U.S. combined revenue from Eylea and Eylea HD fell 12% to $1 billion amid biosimilar competition, while HD Eylea sales reached $596 million, up 52%.
- This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock
Eli Lilly tested tirzepatide (the active ingredient in Zepbound) combined with eloralintide, an experimental drug targeting the amylin hormone rather than GLP-1. After 48 weeks, the combination produced weight loss of up to 23.3%, versus 14.8% with tirzepatide alone and 12.3% with eloralintide alone. However, discontinuation rates due to side effects reached as high as 27%, though Lilly’s Ken Custer noted that high discontinuation was also seen with tirzepatide in a mid-stage trial and that dosing can matter. The author views the results as a net positive but flags a steep valuation, with a market cap above $1 trillion and the stock trading near 40 times trailing earnings after rising around 10% this year.
Related markets
Latest news
- Prime Minister: “After many years, electricity prices are finally falling, based on a very careful assessment of EVN’s financial situation”
At the regular October government session, Prime Minister Lê Minh Hưng acknowledged basic achievements but flagged challenges in controlling inflation and reaching double-digit growth, including low disbursement rates at some ministries and key projects. He stressed that controlling inflation is the top priority for the final two months of the year, warning that growth will not spread to the economy and people if inflation is not contained. On electricity, he said prices are finally falling after many years, based on a careful review of EVN’s financial situation, while fuel tax measures introduced early this year have strongly affected budget revenue. The Ministry of Finance was tasked with monitoring prices, updating inflation scenarios, accelerating VAT reform and proposing CPI targets for localities from 2027, and a decree on petroleum business is to be finalized in November 2026.
- Trump congratulates Democrats on winning both chambers of Congress, pledges cooperation
After Republicans lost control of both the Senate and the House, President Donald Trump told Fox News that Democrats “did a good job” and that the midterm loss was not a major blow to him. He said his administration cannot work with Democrats on every issue but could cooperate on immigration, and claimed the past two years were the best economic period in his presidency’s history. He congratulated Democrats for waiting 11 years for this win. Senator Kirsten Gillibrand said the blue wave was much bigger than she had imagined. Trump said Republicans have a pool of potential 2028 presidential candidates, though it is still too early to identify them.
- Can Marine Systems Named an Authorized Reseller of Amazon Leo
Singapore-based Can Marine Systems has signed an agreement to become an authorized reseller of Amazon Leo, Amazon’s low Earth orbit satellite constellation. It will deliver Amazon Leo connectivity through its Canopus™ Platform as part of managed maritime connectivity and onboard IT services, combining satellite and cellular networks with onboard network policies, crew access controls and remote management. Can Marine remains the customer’s service partner from network design and installation through ongoing support. Amazon Leo’s initial constellation includes more than 3,000 satellites. Director Lim Ding Liang said the goal is to make new networks work within how customers operate their vessels.
- Ministry of Finance outlines price management measures, targets CPI of around 4.5%
At the October regular government press briefing, Deputy Finance Minister Nguyễn Đức Chi said average CPI for the first 10 months rose 4.57%, above the full-year 2026 target of around 4.5%. The Ministry of Finance proposed measures including monitoring and forecasting prices, ensuring supply of essential goods such as fuel, food and medical supplies, coordinating monetary and fiscal policy, cautiously managing state-set prices especially fuel and electricity, and tightening inspections against hoarding and price manipulation. The special consumption tax on gasoline is cut to 0% from Nov. 1, 2026 to March 31, 2027, which is expected to reduce state budget revenue by nearly 7,000 billion VND, while average retail electricity prices fall 2%. The ministry estimates these measures could lower CPI by about 0.5 percentage points in November 2026 versus October and by about 0.08 percentage points in the 2026 average CPI.
- Bitcoin bounces from 7-week low under $76K as Democrats sweep Congress
Bitcoin fell to $75,618 on Bitstamp, a seven-week low, as Democrats won control of both the House and Senate in the US midterm elections, then rebounded to $78,039 within three hours. Total crypto long liquidations over 24 hours reached $288 million. Talos’s Kelly Ye said Bitcoin moved about 1.7% after the polls closed, close to the roughly 1.8% priced in by options, so markets had largely prepared for the result. S&P 500 and Nasdaq 100 futures were both down about 0.3%. Analysts said Bitcoin must defend its 50-week moving average, at $75,733, to avoid a deeper correction, while Ameriprise Financial’s Anthony Saglimbene linked the reaction to concerns over data-center and AI capital spending.
- Warren Buffett Is "Ahead of His Time" Again: Portfolio's Largest Stock Up 25%, Generating Double the Free Cash Flow of Four Top Global Companies Combined
Apple generated about 136 billion USD in free cash flow in the fiscal year ended September 2026, up 38% and well above its 111 billion USD record in 2022, nearly double the combined total of Microsoft, Meta, Alphabet and Amazon over the last four quarters (about 67 billion USD). The gap stems largely from spending: those four firms put over 600 billion USD into fixed assets, mostly AI chips and data centers, while Apple spent only about 9 billion USD, down nearly 30%. Apple shares rose about 25% year to date as of November 2, and Warren Buffett's Berkshire Hathaway still holds 227.9 million Apple shares worth about 66 billion USD, 22% of its equity portfolio as of end-June 2026, though that stake is down about 75% from mid-2023.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.